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Parenteral lipid emulsions, which are made of oils from plant and ﬁsh sources, contain different types of
tocopherols and tocotrienols (vitamin E homologs). The amount and types of vitamin E homologs in
various lipid emulsions vary considerably and are not completely known. The objective of this analysis
was to develop a quantitative method to determine levels of all vitamin E homologs in various lipid
emulsions. An HPLC system was used to measure vitamin E homologs using a Pinnacle DB Silica
normal phase column and an isocratic, n‐hexane:1,4 dioxane (98:2) mobile phase. An optimized
protocol was used to report vitamin E homolog concentrations in soybean oil‐based (Intralipid1,
Ivelip1, Lipofundin
1
N, Liposyn
1
III, and Liposyn
1
II), medium‐ and long‐chain fatty acid‐based
(Lipofundin
1
, MCT and Structolipid1), olive oil‐based (ClinOleic1), and ﬁsh oil‐based (Omegaven1)
andmixture of these oils‐based (SMOFlipid1, Lipidem1) commercial parenteral lipid emulsions. Total
content of all vitamin E homologs varied greatly between different emulsions, ranging from 57.9 to
383.9mg/mL. Tocopherols (a, b, g, d) were the predominant vitamin E homologs for all emulsions, with
tocotrienol content< 0.3%. In all of the soybean emulsions, except for Lipofundin1N, the predominant
vitamin E homolog was g‐tocopherol, which ranged from 57–156mg/mL. ClinOleic1 predominantly
contained a‐tocopherol (32mg/mL), whereas a‐tocopherol content in Omegaven1was higher thanmost
of the other lipid emulsions (230mg/mL).
Practical applications: The information on the types and quantity of vitamin E homologs in various
lipid emulsions will be extremely useful to physicians and healthcare personnel in selecting appropriate
lipid emulsions that are exclusively used in patients with inadequate gastrointestinal function, including
hospitalized and critically ill patients. Some emulsionsmay require vitamin E supplementation in order to
meet minimal human requirements.
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1 Introduction
Parenteral lipid emulsions are oil‐in‐water based suspensions
made from vegetable and/or ﬁsh oils by emulsifying the oils
with phospholipids from egg yolk. Lipid emulsions are mostly
composed of triglycerides along with a variety of other
components that include phospholipids, cholesterol, phytos-
terols, squalene, and fat soluble vitamins. Lipid emulsions
serve primarily as a source of energy and essential fatty acids.
However, they are also an important source of Vitamin E
(tocopherols and tocotrienols) [1–3].
Vitamin E is the generic term for a family of tocopherol
and tocotrienol homologs [4–6]. In nature, eight substances
have been found to possess vitamin E activity. These
substances include a, b, g, and d tocopherols and a, b, g,
and d tocotrienols. All of these compounds feature a
chromanol ring with a hydroxyl group that can donate a
hydrogen atom to reduce free radicals, and a hydrophobic
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side chain that allows for penetration of the compounds into
biological membranes. Tocotrienols differ from tocopherols
by the presence of 3 double bonds on the hydrophobic side
chain. (Figure 1).
Vitamin E homologs have many different biological
activities [4, 7]. Vitamin E is the primary fat‐soluble
antioxidant in the human body [4]. The structure of vitamin
E, with its hydrophobic side chain, makes it unique and
indispensable in protecting cell membranes from oxidant
damage [8, 9]. Due to its preferential accumulation in the
body, a‐tocopherol arguably is the most important vitamin E
homolog believed to modify the course of many oxidative
diseases that include cardiovascular disease [10, 11]. In
addition to their anti‐oxidation properties, several studies
have suggested that vitamin E homologs have important
effects upon platelets, cholesterol metabolism, and the
immune system. For example, tocopherols (g‐tocopherol>
a‐tocopherol) decrease platelet aggregation and LDL oxida-
tion [12, 13]. Tocotrienols have been shown to inhibit
cholesterol synthesis and may reduce the risk of cardiovascu-
lar disease [14–17]. a‐tocopherol inhibits the activity of
protein kinase C (PKC), an enzyme involved in cell
proliferation and differentiation in smooth muscle cells,
platelets, and monocytes [4, 18]. a‐tocopherol has been
shown to decrease adherence of blood components to
endothelium and modulate enzymes involved in prostaglan-
din metabolism [4, 19]. Although vitamin E is referred to as
the fertility vitamin in animals, its deﬁciency is not associated
with a loss of fertility in humans but has been associated with
neuromuscular disease (ie. ataxia, myopathies, neuropa-
thies), immune dysfunction, and anemia [20–22].
Lipid‐rich plants and vegetable oils are the main natural
sources of vitamin E. However, levels of the various vitamin E
homologs differ substantially between oils [23, 24]. a‐
tocopherol is the main source of vitamin E activity found
in supplements and in European diets that are based on olive
and sunﬂower oils, while g‐tocopherol is the most common
vitamin E source in the American diet based on soybean,
canola, and corn oils. Tocotrienols are high in palm, coconut,
and soybean oils. a‐tocopherol is the predominant vitamin E
homolog in ﬁsh oil [25]. However, total vitamin E and
a‐tocopherol content vary greatly (ie. 0.20–2.25mg/100g)
among different species of ﬁsh [25], likely reﬂecting their
different diets. Commercially available parenteral lipid
emulsions utilize soybean oil, palm or coconut oil (source
of medium‐chain triglycerides), olive oil, and/or ﬁsh oil.
However, levels of vitamin E homologs in these emulsions
have not been systematically quantiﬁed. The primary
objective of this study was to develop a method to quantify
the eight vitamin E homologs and to use this method to
measure the levels of the homologs in the major commercial
lipid emulsions used to treat patients.
Several methods have been used to quantify tocopherols
and tocotrienols from oil, bio‐ﬂuid and tissue, but the
quantiﬁcation of vitamin E from lipid emulsion had not been
reported. In this paper, we report an accurate quantiﬁcation
method for tocopherols and tocotrienols from eleven
commercially available lipid emulsions. The method includes
liquid‐liquid extraction and separation on a normal‐phase
HPLCwith a ﬂuorescence detector. The quantiﬁcation of the
major andminor vitamin E homologs was achieved separately
using different external standard curves in the presence of
the internal standard.
2 Materials and methods
2.1 Materials
Tocopherols (a, b, g and d homologs) were purchased from
Calbiochem, USA. Tocotrienols (a, b, g and d homologs)
were purchased from Davos Life Science Pte Ltd, Singapore.
rac‐Tocol was purchased from Matreya LLC, USA.
The purity of all reference standards was at least 95%.
Hexane (CHROMASOLV1, for HPLC,  97.0%), metha-
nol (anhydrous, 99.8%), 2, 6‐Di‐tert‐butyl‐4‐methylphenol
(BHT,  99.0%) and all other reagents were purchased from
Sigma‐Aldrich (St. Louis, MO, USA). The reference
standard and internal standard were dissolved in the hexane
solution. All the standard stocks were ﬂushed with N2 and
stored at 20°C before use.
Figure 1. Structure of tocopherols and tocotrienols.
All Vitamin E homologs (tocopherols and tocotrienols) contain a
chromanol ring and a hydrophobic side chain. In tocopherols (T), the
side chain is made up of a phytylin group, whereas tocotrienols (T3)
consist of an isoprenyl group with three double bonds. The T and T3
are further classiﬁed as either an a, b, g, or d homolog, as shown in
the ﬁgure.
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2.2 Lipid emulsions
Intralipid1, Structolipid
1, SMOFlipid1, and Omegaven1
were from Fresenius Kabi (Bad Homburg, Germany);
Lipofundin
1
N, Lipofundin
1
MCT and Lipidem
1
were
from B. Braun (Melsungen, Germany); Liposyn
1
II and
Liposyn
1
III were from Hospira, Inc. (Lake Forest, IL,
USA); Ivelip1 and ClinOleic1 were from Baxter Health-
care Corporation (Deerﬁled, IL, USA). The lipid emulsions
are based upon soybean oil, medium‐chain triglyceride
(MCT) oils,olive oil, ﬁsh oil, and a mixture of these oils
(Table 1).
2.3 External standard curve
Stocks of a standard mixture containing all eight vitamin E
homologs (200mg/mL for each compound) were diluted in
hexane to generate standard curves for the analysis of the
vitamin E homologs. From our preliminary experiments, we
realized that it was not possible to utilize a single external
standard equation to accurately quantify the vitamin E
homologs from lipid emulsions because of extreme
variations in the concentrations (0.01 to 300mg/mL or
higher) of various vitamin E homologs in the emulsions.
We found that the HPLC ﬂuorescent signals of the test
compounds were not completely linear, especially at
extremely low concentrations. A single standard curve
would potentially overestimate the quantity of a vitamin E
homolog that was present in low concentrations. In order
to solve this problem, we generated two sets of external
standard curves in the presence of different amounts of
the internal standard. One set of the standards mixture
was for the high vitamin E concentrations, whereas the
other set was for the low vitamin E concentrations. For high
vitamin E concentrations, a stock solution was diluted
in hexane to 50.000, 25.000, 12.500, 6.250, 3.125, 1.563
and 0.781mg/mL, whereas for low vitamin E concentra-
tions, a stock standard mixture was diluted to 0.781, 0.391,
0.195, 0.098, 0.049, 0.024 and 0.012mg/mL. The high
and low standard dilutions also contained rac‐Tocol
(internal standard) at 5mg/mL and 1mg/mL, respectively.
A standard curve was generated (triplicate runs) using
optimized HPLC conditions as described below, and the
concentration of each vitamin E homolog was calculated
using an equation Y¼ aXþ b (where Y¼ concentration of
the vitamin E homolog to be determined (mg/mL); X¼ ratio
of peak area of the vitamin E homolog (ASample) to the
peak area of corresponding internal standard (AI‐Standard);
and a¼ slope of the standard curve, b¼ intercept of the
standard curve). The results obtained from both standard
curves for high and low concentration are summarized in
Table 2.
Table 1. Content of lipid emulsions
Emulsions Manufacturer Lot No. Major component
Soybean oil‐based
Intralipid1 Fresenius Kabi (DE) 10BK7082 SO 20 g/100mL and 1.2 g EYPL
Ivelip1 Baxter Healthcare Corporation (BE) 08K25A92 SO 20 g/100mL and 1.2 g EYPL
Lipofundin
1
N B. Braun (DE) 9173A184 SO 20 g/100mL and 1.2 g EYPL
Liposyn
1
III Hospira, Inc. (US) 70913DW SO 20 g/100mL and 1.2 g EYPL
Liposyn
1
II Hospira, Inc. (US) 74906DW Mixture of SO (50%) and SFO (50%),
20 g/100mL, and 1.2 g EYPL
Medium‐ & Long‐chain fatty acid‐based
Lipofundin
1
MCT B. Braun (DE) 8494A181 Mixture of SO (50%) and MCT (50%),
20 g/100mL, and 1.2 g EYPL
Structolipid1 Fresenius Kabi (DE) 10CD2533 Interesterified mixture of equimolar amounts
of LCT 64% (w/w) and MCT 36% (w/w),
20 g/100mL, and 1.2 g EYPL
Olive oil‐based
ClinOleic1 Baxter Healthcare Corporation (FR) 09D09A91 Mixture of OO (80%) and SO (20%),
20 g/100mL, and 1.2 g EYPL
Fish oil‐based
SMOFlipid1 Fresenius Kabi (DE) 16CG0134 Mixture of OO (25%), SO (30%), FO (‘5%),
and MCT (30%) 20 g/100mL; and 1.2 g of EYPL
Lipidem1 B. Braun (DE) 9304A181 Mixture of SO (40%), FO (10%),
and MCT (50%) 20 g/100mL; and 1.2 g of EYPL
Omegaven1 Fresenius Kabi (DE) 16CA0022 FO 10 g/100mL and 1.2 g of EYPL
Abbreviations: BE, Belgium; FR, France; DE, Germany; US, United States; SO, soybean oil; SFO, safﬂower oil; OO, olive oil; FO, ﬁsh oil;
MCT, medium‐chain triglycerides; LCT, long‐chain triglycerides; EYPL, egg yolk phospholipids.
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2.4 Lipid emulsion extraction (for high vitamin E
concentration)
200mL of lipid emulsion (in triplicate) was placed into
10 13mm Pyrex tubes with Teﬂon‐lined screw caps. To
these tubes, 40mL of Internal Standard (IS) (C¼ 250mg/mL,
in hexane), 800mL of methanol, and then 2000mL of hexane
(0.05% BHT) were added. Tubes were vortexed for 1min
and then centrifuged at 1400 g for 20min to separate the
aqueous and non‐aqueous layers (2mL). 200mL of the
top layer (non‐aqueous layer) was transferred to the HPLC
sample vial for HPLC analysis.
2.5 Lipid emulsion extraction (for low vitamin E
concentration)
200mL of lipid emulsion (in triplicate) was added to the
10 13mm Pyrex tubes with Teﬂon‐lined screw caps. To
these tubes, 20mL of IS (C¼ 10mg/mL, in hexane), 800mL
of methanol, and then 2000mL of hexane (0.01% BHT) were
added. Tubes were vortexed for 1min and then centrifuged at
1400 g for 20min to separate aqueous and non‐aqueous
layers. The entire top layer was transferred to a clean glass
tube and dried under N2 ﬂow. The residues were dissolved in
200mL of hexane and then transferred to the HPLC sample
vial for analysis.
2.6 HPLC separation and quantiﬁcation
The HPLC system (SHIMADZU, JP) consisted of a LC‐
20AT pump, a SIL‐20AC auto sampler, and a DGU‐20A
degasser and was equipped with a RF‐10A ﬂuorescence
detector and a SPD‐M20A diode array detector. The
wavelengths of the detector were set at 292nm for excitation
and 330nm for emission for the identiﬁcation and quantiﬁca-
tion of the vitamin E homologs. A Pinnacle DB silica normal
phase column (100 2.1mm, 1.9mm, Restek, USA) was
used. The isocratic mobile phase contained 2% of 1, 4‐dioxane
and 98% of n‐hexane, and the ﬂow rate was adjusted to
300mL/min. Tocopherol and tocotrienol peaks were identiﬁed
by comparing their retention time to the reference standards.
Concentrations of the vitamin E homologs were calculated
using the external standard equations as described above.
We also evaluated the accuracy of the vitamin E
homolog analysis (% recovery) by spiking the standard
mixture (including: a‐tocopherol 150mg/mL, b‐tocopherol
50mg/mL, g‐tocopherol 30mg/mL, d‐tocopherol 4mg/mL,
a‐tocotrienol 30mg/mL, b‐tocotrienol 4mg/mL, g‐tocotrienol
10mg/mL and d‐tocotrienol 50mg/mL) into lipid emul-
sions. Recovery was calculated by the following equation:
R%¼ (Cse ‐Ce)/Cs 100, where R (%) is the percent
recovery of spiked‐in standard; Cse is the vitamin E content
in spiked emulsion; Ce is the vitamin E content in the
emulsion; and Cs is the content of the vitamin E standard
added to the emulsion.
3 Results and discussion
It is important to develop analytical methods that allow for
quantiﬁcation of all of the individual homologs of vitamin E.
Use of HPLC with both normal phase (NP) and reversed
phase (RP) column separation are the most common
techniques used for the analysis of tocopherols and
tocotrienols [26–28]. To obtain higher sensitivity, various
HPLC detectors, including ultraviolet (UV), ﬂuorescence,
evaporative light scattering detection (ELSD), and electro-
chemical detection have been described in the literature
for vitamin E analysis. The ﬂuorescence detector appears
to be more sensitive and selective than the other detectors
[29, 30]. Several studies evaluated protocols for sample
preparation, liquid‐liquid extraction, and solid phase
Table 2. External standard equation parameters
Compounds
For major components (0.8–50.0mg/mL) For minor components (0.01–0.80mg/mL)
a b R2 a b R2
a‐T 8.5286 0.8572 0.9994 9.6901 0.0436 0.9528
a‐T3 8.4591 0.9297 0.9994 9.8504 0.0373 0.9494
b‐T 6.3785 0.3098 0.9993 2.4708 0.0147 0.9914
g‐T 6.1502 0.2938 0.9993 2.4220 0.0137 0.9908
b‐T3 6.4720 0.4399 0.9996 2.6936 0.0138 0.9913
g‐T3 6.4717 0.4458 0.9996 2.8990 0.0071 0.9926
d‐T 3.8884 0.2641 0.9996 0.9893 0.0012 0.9996
d‐T3 3.7912 0.3001 0.9994 0.9895 0.00005 0.9997
Note Equation: y¼ axþ b. y: concentration (mg/mL) where a¼ slope of the standard curve, x¼ peak area ratio (ASample/AI‐Standard) and
b¼ intercept of the standard curve.
T: tocopherols; T3: tocotrienols.
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separation with or without saponiﬁcation [30, 31]. However,
these studies report variable recoveries of different
Vitamin E homologs. The internal standards are widely
used to compensate for the effect of various analytical errors,
including sample size ﬂuctuations; however, variations in the
recovery of the internal standard and vitamin E homologs
during the extraction process strongly affect the quantiﬁca-
tion. Thus, sample preparation procedures need to be
optimized to accurately analyze all Vitamin E homologs in a
single run.
In a recent study, Amaral et al. (2005) compared the
soxhlet extraction and the saponiﬁcation‐extraction method,
and found that liquid extraction (solid‐liquid or liquid‐liquid)
provided a comparable recovery of vitamin E homologs.
However, the recovery of various vitamin E homologs varied
and appeared to be sub‐optimal. From these studies, it
appeared that the extraction of vitamin E homologs during
sample preparation for HPLC analysis was crucial, and, if not
performed optimally, could affect the quantiﬁcation of the
compounds. Considering the hydrophobic properties of the
vitamin E homologs and the composition of the various lipid
emulsions, we used a liquid‐liquid extraction protocol
employing methanol and hexane to prepare samples for
HPLC analysis. The use of the methanol accelerated two‐
layer separation and also removed the polar component from
the sample. We ﬁrst evaluated the effect of varying methanol
amounts (200–1200mL) with hexane (2000mL) to extract
vitamin E homologs from the standard mixtures (containing
rac‐Tocol). The results are shown in Table 3. Our data
indicate that the amount of methanol used in the extraction
can affect the quantiﬁcation of the vitamin E homologs.
800mL of methanol appeared to be optimal, as less than
800mL of methanol hindered separation of the methanol and
hexane layers, whereas a volume higher than 800mL resulted
in no further improvement in the recovery of the vitamin E
homologs. We, therefore, used 800mL of methanol for the
extraction of the vitamin E homologs in our subsequent
experiments. As explained in the Methods section, we
generated two sets of external standard curves in the
presence of different amounts of the internal standard to
generate equations for estimating the concentrations. One
set of the standards mixture was used for the samples
with high vitamin E concentrations, whereas another set was
used for the samples with low vitamin E concentrations.
The data clearly indicate that this approach resulted in a
linear relationship between the detection signal and peak
area for different isomers. Furthermore, the limit of detection
(LOD) of this method was estimated by determining a
concentration that generated a peak ﬁve‐fold higher than
the baseline noise level at the optimized HPLC condition,
with an injection volume of 5mL. The results are listed in
Table 4. The data demonstrate that the detection limit was
directly related to the vitamin E homolog structure, which was
mainly affected by the position of the methyl substitute in
the benzene ring.
The results reported in Table 4 indicate that the
procedure for vitamin E homolog analysis resulted in recovery
of tocopherols in the 984% to 107 3% range and recovery
of tocotrienols in 89 1% to 108 3% range.
The natural vitamin E contents of the lipid emulsions are
signiﬁcantly affected by the oil species used to manufacture
the emulsions. For example, the predominant vitamin E
homolog in soybean oil is g‐tocopherol, but in olive and ﬁsh
oil it is a‐tocopherol [32–34]. The content of vitamin E
homologs in oils are also further inﬂuenced by harvesting,
processing, and storage. Thus, the vitamin E homolog
composition proﬁle of commercially available lipid emulsions
made from different oils by different manufactures may
exhibit large variations in vitamin E content [35–40]. The
vitamin E contents of the lipid emulsions may also be
inﬂuenced by the addition of exogenous vitamin E (usually
a‐tocopherol), which may be added to the lipid emulsions
to minimize oxidation of the fatty acids. With the vitamin E
quantiﬁcation method described in this report, we analyzed
the tocopherol and tocotrienol content of 11 commercially
available lipid emulsions (Table 1 and Table 5). Although
Table 3. Affect of methanol volume on the recovery (%) of tocopherols and tocotrienolsa,b
Methanol 200mL 400mL 600mL 800mL 1000mL 1200mL
a‐T 104.1 104.5 101.6 105.1 110.8 113.9
a‐T3 99.7 101.9 99.2 99.6 104.0 104.7
b‐T 95.0 95.2 93.3 95.5 100.1 101.2
g‐T 96.6 96.4 94.6 96.4 101.3 102.6
b‐T3 97.9 105.0 100.2 95.2 101.4 95.9
g‐T3 110.6 108.2 105.1 106.6 110.6 109.7
d‐T 100.3 100.3 97.3 99.9 104.1 102.9
d‐T3 94.9 94.8 91.6 92.1 91.4 87.1
aStandard mixture used in this experiment: a‐T: 150mg/mL; a‐T3: 300mg/mL; b‐T: 50mg/mL; g‐T: 30mg/mL; b‐T3: 4mg/mL; g‐T3: 10mg/
mL; d‐T: 4mg/mL and d‐T3: 50mg/mL.
bData shown in the Table is % to the theoretical concentration.
T: tocopherols; T3: tocotrienols.
Eur. J. Lipid Sci. Technol. 2015, 117, 15–22 Vitamin E homologs in lipid emulsions 19
 2014 The Authors. European Journal of Lipid Science and
Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.ejlst.com
different vitamin E homologs have been previously analyzed
in different lipid emulsions [35, 40], to our knowledge this is
the ﬁrst study to report the content of all 8 vitamin E
homologs in commercial lipid emulsions based upon different
oils. The samples were prepared using liquid‐liquid extrac-
tion protocols for both major and minor components, as
described above, and separately run on the HPLC along with
corresponding standard mixtures (major or minor compo-
nent dilutions). An example of a HPLC chromatograph for
identifying the major and minor components of tocopherol
and tocotrienol homologs is provided for Liposyn1 III
(soybean oil emulsion) in Figure 2 (A–C). Using this
procedure, all the lipid emulsions were analyzed and the
data are presented in Table 5.
Tocopherols (a, b, g, d) were the predominant vitamin E
homologs for all emulsions, with tocotrienol content<0.3%.
In all of the soybean emulsions, except for Lipofundin1 N
and Lipofundin1MCT, the predominant vitamin E homolog
was g‐tocopherol. In Lipofundin1 N and Lipofundin1
MCT, the predominant vitamin E homolog was a‐tocopher-
ol. The high levels of a‐tocopherol in this soybean emulsion
are consistent with exogenous supplementation of the
emulsion with a‐tocopherol. The total vitamin E contents
of the soybean oil‐based lipid emulsions were highly variable,
ranging from 124–384mg/mL. The vitamin E content of the
unsupplemented soybean oil‐based emulsions (Intralipid1,
Ivelip1, Liposyn1 II and III) was less variable and ranged
from 124–186mg/mL. Liposyn1 II had the lowest vitamin E
content of the soybean oil‐based lipid emulsions (mean¼
124.81mg/mL), which reﬂects its content of both soybean oil
and safﬂower oil.
The content of a‐, b‐, g‐, d‐tocopherols in different lipid
emulsions, as reported in Table 5, is comparable to that
of previously reported concentrations for Intralipid
1
[35],
Lipidem1 [35], Structolipid1 [40] and ClinOleic1 [40];
Table 4. Method detection limit and recovery
Compounds LOD (mg/mL)a Recovery (%)b
a‐T 0.098 100.9 2.4
a‐T3 0.098 93.8 2.2
b‐T 0.012 97.5 3.7
g‐T 0.012 106.6 2.7
b‐T3 0.012 107.5 2.9
g‐T3 0.012 96.1 2.1
d‐T <0.006 98.1 2.8
d‐T3 <0.006 88.8 1.2
aSensitivity of the method was estimated by determining the lowest
limit of detection (LOD) concentration which generated a peak
ﬁve‐fold higher than the baseline noise level (injection volume for
HPLC: 5mL).
bRecovery was evaluated by spiking standards into the lipid
emulsions.
T: tocopherols; T3: tocotrienols.
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however, we found higher amounts of a‐ and g‐tocopherols
in Lipofundin1 N and Lipofundin1MCT compared to that
previously reported [35, 40]. The higher a‐tocopherol
content of Lipofundin1 N and Lipofundin1 MCT found
in the present investigation, as compared to values reported
by Wanten et al. (29mg/mL) [40] and Steger et al.
(21.76 2.10mg/mL) [35], reﬂects supplementation of the
emulsion with exogenous a‐tocopherol. The manufacturer
likely added exogenous a‐tocopherol to the emulsions
sometime following the previous studies. The predominant
tocopherol of the olive oil‐based lipid emulsion, ClinOleic1,
was a‐tocopherol. This lipid emulsion had the lowest content
of vitamin E, which reﬂects its content in olive oil. Our data
for ClinOleic
1
closely resemble that reported by other
investigators [38–40]. It is also important to note that olive
oil contains predominantly monounsaturated fatty acids,
which are less susceptible to oxidation compared to
polyunsaturated fatty acids. Thus, there may have been less
evolutionary need for a lipid antioxidant in olive oil. As
reported by others [36, 40], our investigation also found a‐
tocopherol to be the predominant vitamin E homolog in the
ﬁsh oil‐containing emulsions. Despite Omegaven1 being a
10% lipid emulsion while the other emulsions were all 20%
emulsions, its content of vitamin E (mostly a‐tocopherol) was
comparable or higher than most of the other lipid emulsions.
4 Conclusion
The use of the optimized liquid‐liquid extraction procedure
and a normal‐phase HPLC separation with a ﬂuorescence
detector provided high sensitivity and selectivity for
the determination of tocopherols and tocotrienols. The two
external standard curves, in conjunction with an internal
standard, provided an accurate quantiﬁcation for the
tocopherols and tocotrienols in the lipid emulsions. Lipid
emulsions contained variable amounts of tocopherols.
Tocotrienol content of the lipid emulsions was minimal or
not detectable. Additional studies will evaluate the levels of
vitamin E homologs in tissues, determine alterations induced
by disease, and evaluate the effects of lipid emulsion infusion
upon tissue levels.
The authors wish to thank Elaine Bammerlin for providing the
editorial assistance. This study was supported by a grant from
Baxter Healthcare Corporation, Deerﬁeld, IL 60015, USA.
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